chronic kidney disease stage 3-4 with hyperkalaemia
Metabolic · 2022–2023
2decisions
1medicine
2carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| patiromer Initial treatment of adult patients with chronic kidney disease (CKD) Stage 3-4, with chronic hyperkalaemia (at least two episodes of serum potassium 6.0… | Mar 2023 | Recommended with restriction | input received |
| patiromer Initial treatment of adult patients with chronic kidney disease (CKD) Stage 3–4 with chronic hyperkalaemia (at least 2 episodes of serum potassium ≥6.0 mmol/L… | Nov 2022 | Not recommended | 1 individuals |
What the PBS pays
$4M in government benefit over 2024–25, across 10,760 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| patiromer | $4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.